- Home
- PYN vs DARE Comparison
PYN vs DARE Comparison
Compare PYN & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- DARE
- Stock Information
- Founded
- PYN 2002
- DARE N/A
- Country
- PYN United States
- DARE United States
- Employees
- PYN N/A
- DARE N/A
- Industry
- PYN Investment Managers
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- DARE Health Care
- Exchange
- PYN Nasdaq
- DARE Nasdaq
- Market Cap
- PYN 33.5M
- DARE 27.9M
- IPO Year
- PYN N/A
- DARE N/A
- Fundamental
- Price
- PYN $5.91
- DARE $3.17
- Analyst Decision
- PYN
- DARE Strong Buy
- Analyst Count
- PYN 0
- DARE 4
- Target Price
- PYN N/A
- DARE $20.33
- AVG Volume (30 Days)
- PYN 19.9K
- DARE 25.7K
- Earning Date
- PYN 01-01-0001
- DARE 03-27-2025
- Dividend Yield
- PYN 5.07%
- DARE N/A
- EPS Growth
- PYN N/A
- DARE N/A
- EPS
- PYN N/A
- DARE N/A
- Revenue
- PYN N/A
- DARE $1,881,316.00
- Revenue This Year
- PYN N/A
- DARE N/A
- Revenue Next Year
- PYN N/A
- DARE $136.52
- P/E Ratio
- PYN N/A
- DARE N/A
- Revenue Growth
- PYN N/A
- DARE 88.13
- 52 Week Low
- PYN $4.84
- DARE $2.67
- 52 Week High
- PYN $6.60
- DARE $7.56
- Technical
- Relative Strength Index (RSI)
- PYN 65.73
- DARE 50.64
- Support Level
- PYN $5.79
- DARE $2.95
- Resistance Level
- PYN $5.89
- DARE $3.31
- Average True Range (ATR)
- PYN 0.05
- DARE 0.15
- MACD
- PYN 0.01
- DARE 0.01
- Stochastic Oscillator
- PYN 100.00
- DARE 61.11
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.